Renfei Zhang

Kevin Han, Renfei Zhang, Kathy Wei et al.

LLM agents have incredible potential for scientific discovery applications. However, the performance of LLM agents on real-world, small molecule drug design (SMDD) tasks across diverse chemistries and targets is unclear. Current evaluation methods are either ad hoc, too simple for real-world discovery, limited in scale, or restricted to single-turn question answering. In effort to standardize the evaluation of LLM agents on small molecule design, we introduce SMDD-Bench, a challenging, multi-turn, long-horizon agentic benchmark consisting of 502 guaranteed-solvable task instances spanning 5 task types: 2D Pharmacophore Identification, Interaction Point Discovery, Scaffold Hopping, Lead Optimization, and Fragment Assembly. SMDD-Bench tasks span a wide region of chemical space and involve 102 unique protein targets. Completely solving the benchmark would require having strong chemical and biological reasoning and 3D intuition, understanding specialized tool use, and displaying planning expertise over a limited number of oracle calls. We benchmark 7 frontier open and closed source LLMs and find even the most performant LLM, GPT5.4, solves only 40.2\% of tasks. We hope SMDD-Bench provides a standardized testbed to invigorate the field towards training and evaluating LLM agents for fully autonomous computational drug design. We host a public leaderboard at smddbench.com .

Renfei Zhang, Manasa Kaniselvan, Niloofar Mireshghallah

Reinforcement learning (RL) is often credited with improving language model reasoning and generalization at the expense of degrading memorized knowledge. We challenge this narrative by observing that RL-enhanced models consistently outperform their base and supervised fine-tuned (SFT) counterparts on pure knowledge recall tasks, particularly those requiring traversal of hierarchical, structured knowledge (e.g., medical codes). We hypothesize these gains stem not from newly acquired data, but from improved procedural skills in navigating and searching existing knowledge hierarchies within the model parameters. To support this hypothesis, we show that structured prompting, which explicitly guides SFTed models through hierarchical traversal, recovers most of the performance gap (reducing 24pp to 7pp on MedConceptsQA for DeepSeek-V3/R1). We further find that while prompting improves final-answer accuracy, RL-enhanced models retain superior ability to recall correct procedural paths on deep-retrieval tasks. Finally our layer-wise internal activation analysis reveals that while factual representations (e.g., activations for the statement "code 57.95 refers to urinary infection") maintain high cosine similarity between SFT and RL models, query representations (e.g., "what is code 57.95") diverge noticeably, indicating that RL primarily transforms how models traverse knowledge rather than the knowledge representation itself.

Renfei Zhang, Mohit Pandey, Artem Cherkasov et al.

The scalability of pool-based active learning is limited by the computational cost of evaluating large unlabeled datasets, a challenge that is particularly acute in virtual screening for drug discovery. While active learning strategies such as Bayesian Active Learning by Disagreement (BALD) prioritize informative samples, it remains computationally intensive when scaled to libraries containing billions samples. In this work, we introduce BALD-GFlowNet, a generative active learning framework that circumvents this issue. Our method leverages Generative Flow Networks (GFlowNets) to directly sample objects in proportion to the BALD reward. By replacing traditional pool-based acquisition with generative sampling, BALD-GFlowNet achieves scalability that is independent of the size of the unlabeled pool. In our virtual screening experiment, we show that BALD-GFlowNet achieves a performance comparable to that of standard BALD baseline while generating more structurally diverse molecules, offering a promising direction for efficient and scalable molecular discovery.